STOCK TITAN
  1. Home
  2. News
  3. ORYZF

Oryzon Genomics S.A. - ORYZF STOCK NEWS

IMPACT
SENTIMENT
ORYZF : OTC
ORYZON Enrolls First Patient in EVOLUTION, a Phase IIb Clinical Trial With Vafidemstat in Schizophrenia
clinical trial
IMPACT
SENTIMENT
ORYZF : OTC
ORYZON Publishes Paper in ACS Pharmacology & Translational Science Supporting Best-in-Class Performance of Iadademstat in Oncology
IMPACT
SENTIMENT
ORYZF : OTC
ORYZON to Present New Clinical Data and Corporate Updates at International Conferences in November and December
conferences clinical trial
IMPACT
SENTIMENT
ORYZF : OTC
ORYZON Reports Results and Corporate Update for Quarter Ended September 30, 2021
IMPACT
SENTIMENT
ORYZF : OTC
ORYZON enrolls first patient in the US in PORTICO, a Phase IIb clinical trial with vafidemstat in Borderline Personality Disorder
clinical trial
IMPACT
SENTIMENT
ORYZF : OTC
ORYZON presents safety and efficacy data of vafidemstat from the Phase II SATEEN trial in multiple sclerosis at ECTRIMS-2021
IMPACT
SENTIMENT
ORYZF : OTC
ORYZON to Present New Clinical Data and Corporate Updates at International Conferences in September and October
conferences clinical trial
IMPACT
SENTIMENT
ORYZF : OTC
Oryzon Announces $1 Million Grant From Kabuki Syndrome Philanthropists to Support a Precision Medicine Phase I/II Trial With Vafidemstat
IMPACT
SENTIMENT
ORYZF : OTC
ORYZON Reports Results and Corporate Update for First Half Ended June 30, 2021
IMPACT
SENTIMENT
ORYZF : OTC
ORYZON receives approval to start EVOLUTION Phase IIb trial with vafidemstat in schizophrenia
Stock ORYZF logo
Oryzon Genomics S.A.

OTC:ORYZF

ORYZF Rankings

#4822 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ORYZF Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Health Technology, Biotechnology
Spain
Cornella De Llobregat